SCHEDULE 13D/A: Perceptive Advisors Increases Stake in Solid Biosciences to 15.6% Following $20.2 Million Share Acquisition

Perceptive Advisors LLC and its affiliates have significantly increased their beneficial ownership in Solid Biosciences Inc. to 15.6% of outstanding common stock, acquiring 5 million shares for $20.2 million in a recent underwritten offering.

Summary

• Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd., and Perceptive Xontogeny Venture Fund, LP collectively reported beneficial ownership of 11,934,679 shares of Solid Biosciences Inc. common stock, representing 15.6% of the class.
• This filing is an Amendment No. 8 to Schedule 13D, updating previous ownership disclosures.
• On February 19, 2025, Perceptive Life Sciences Master Fund, Ltd. acquired 5,000,000 shares of Common Stock at $4.03 per share, totaling $20.2 million, as part of an underwritten public offering conducted by Solid Biosciences Inc.
• The acquisition was funded by the working capital of the Master Fund.
• The percentage ownership is based on 76,318,810 outstanding shares of Common Stock, as reported by Solid Biosciences Inc. in its Prospectus Supplement filed on February 18, 2025.
• Adam Stone, Chief Investment Officer of Perceptive Advisors, holds stock options for 62,433 shares, with 28,033 currently exercisable (or exercisable within 60 days), which are included in the beneficial ownership calculation for certain reporting persons.
• Perceptive Life Sciences Master Fund, Ltd. is entitled to receive director compensation related to Mr. Stone's board service through a partial management fee offset.
• In connection with the offering, the Master Fund entered into a 60-day lock-up agreement with the underwriters, restricting the sale or transfer of shares without their prior consent.

Sentiment

Score: 7

Explanation: The document indicates a significant investment by a reputable life sciences fund, Perceptive Advisors, in Solid Biosciences Inc. This suggests strong investor confidence and successful capital raising for the company. The lock-up agreement is a standard procedure and not a negative indicator of the company's health.

Positives

• A significant investment of $20.2 million by a major institutional investor like Perceptive Advisors indicates confidence in Solid Biosciences Inc.'s future prospects.
• The acquisition was part of an underwritten offering, suggesting the company successfully raised capital.

Negatives

• The lock-up agreement restricts the Master Fund from selling shares for 60 days, limiting liquidity for that period.

Risks

• The Master Fund is subject to a 60-day lock-up agreement, restricting its ability to sell or transfer shares of Common Stock or related securities without prior consent from the underwriters.

Future Outlook

The document primarily details a change in beneficial ownership and does not provide forward-looking statements or guidance from Solid Biosciences Inc. It indicates Perceptive Advisors' continued investment in the company.

Industry Context

This filing reflects a significant investment by a specialized life sciences fund, Perceptive Advisors, into a biotechnology company, Solid Biosciences Inc. Such investments are common in the biotech sector, where capital raises are frequent for funding research and development. The substantial stake taken by Perceptive suggests a belief in Solid Biosciences' long-term potential within the competitive biotechnology landscape.

Stakeholder Impact

• Shareholders: The significant investment by Perceptive Advisors may be viewed positively, potentially boosting investor confidence and share price stability. The capital raise itself dilutes existing shares but provides funding for company operations.
• Company (Solid Biosciences Inc.): The successful underwritten offering provides capital for operations and strategic initiatives.

Next Steps

• The Master Fund is subject to a 60-day lock-up period, during which it cannot sell or transfer shares without underwriter consent.

Key Dates

Recommendation

Keywords

Solid Biosciences Inc., Perceptive Advisors, Joseph Edelman, Schedule 13D, Common Stock, Share Acquisition, Underwritten Offering, Institutional Investment, Biotechnology, Lock-up Agreement, Beneficial Ownership